At the 85th Scientific Sessions of the American Diabetes Association, research revealed that CarigSema, a new drug combining Cagrilintide and Semaglutide, can help patients with type 2 diabetes lose 15% of their body weight while normalizing blood sugar levels. The REDEFINE 2 study, led by Professor Carel LeRoux, indicates that patients feel more functional and experience manageable side effects. CarigSema is seen as a promising follow-on treatment for those already addressing obesity and diabetes with existing medications like Ozempic and Wegovy, aiming for better disease management overall.
"The REDEFINE 2 study showed that CagriSema, a new treatment in development for the disease of obesity, can allow patients with type 2 diabetes lose 15pc body weight, while putting their blood sugar levels back in the normal range," said Professor Carel LeRoux, a leading weight-loss researcher at the UCD Conway Institute, and a principal investigator on the study.
"What patients often tell us is that they again can do all the things they want because they feel so much more functional," said Prof Le Roux.
"We also see that the side effects are manageable and clinicians are getting much better at reducing common side effects.
"Taken together, this will allow clinicians to control the disease of obesity, which will allow us to disrupt the disease of type 2 diabetes."
Collection
[
|
...
]